Empagliflozin Dose: Adults 50-64 Need No Age Adjustment
Standard empagliflozin dose is 10 mg daily, up to 25 mg for T2D. Heart failure and CKD stay fixed at 10 mg; renal function guides dosing, not age.
Empagliflozin
22 source-based articles maintained by the HealthRX.com Editorial Team.
22articles
5topic areas covered
May 26, 2026latest review
Empagliflozin library
Showing 22 of 22 clinical reviews.
Empagliflozin Pharmacokinetics: Why Blood Levels and Glucose Effects Diverge
Empagliflozin blood levels can rise as kidney function declines while urinary glucose loss falls. Primary study data explain the difference.
Jardiance (Empagliflozin) Dosing in Hepatic Impairment
Evidence-based guide to empagliflozin dosing in patients with liver disease, including pharmacokinetic data, FDA labeling, and clinical considerations for mild, moderate, and severe hepatic impairment.
Jardiance (Empagliflozin) Food & Supplement Interactions
Evidence-based guide to empagliflozin food and supplement interactions, including alcohol, grapefruit, diuretics, potassium, and common supplements that may affect SGLT2 inhibitor safety or efficacy.
Jardiance (Empagliflozin) Manufacturing, Supply & Shortage History
A detailed look at how Jardiance (empagliflozin) is manufactured, its global supply chain, and a complete history of shortages reported to the FDA, with clinical context from EMPA-REG OUTCOME and beyond.
Jardiance (Empagliflozin) Monitoring in Adults 65 and Older
Evidence-based monitoring guide for empagliflozin (Jardiance) in geriatric patients 65+, covering renal function, volume status, ketoacidosis screening, and deprescribing considerations.
Jardiance (Empagliflozin) Regulatory Status: US, EU, Canada, and UK Approvals
A complete regulatory timeline for empagliflozin (Jardiance) across the FDA, EMA, Health Canada, and MHRA, including approved indications for type 2 diabetes, heart failure, and chronic kidney disease.
Jardiance Autoimmune Disease Considerations: What Clinicians and Patients Need to Know
A clinical review of empagliflozin (Jardiance) use in patients with autoimmune conditions, covering immunological mechanisms, trial data, drug interactions, and monitoring protocols.
Jardiance Bone Health and Density Impact: What the Evidence Shows
Does Jardiance (empagliflozin) affect bone density or fracture risk? A review of the clinical trial data, mechanisms, and monitoring guidance for patients and prescribers.
Jardiance Cancer Risk Signal Review: What the Evidence Actually Shows
A clinician-level review of empagliflozin (Jardiance) and cancer risk signals, covering EMPA-REG OUTCOME, FAERS pharmacovigilance data, FDA labeling history, and current prescribing guidance.
Jardiance Cardiovascular Impact Long-Term: What the Evidence Actually Shows
A clinician-level review of empagliflozin's long-term cardiovascular effects, covering EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, mechanism of action, and practical prescribing guidance.
Jardiance for Renal Protection: What the Trials Show
EMPA-KIDNEY found a 28% reduction in kidney/CV risk with Jardiance. Learn why eGFR dips at first, who benefits, and FDA contraindications.
Jardiance Hair and Skin Changes: What Empagliflozin Actually Does
A deep dive into empagliflozin (Jardiance) and its known effects on hair, skin, and related dermatologic conditions, including genital mycotic infections, urinary changes, and rare rash reports.
Jardiance Mental Health and Mood Impact: What the Evidence Actually Shows
A clinical review of empagliflozin (Jardiance) and its effects on mental health, mood, depression, anxiety, and cognitive function. Covers EMPA-REG OUTCOME, DKA risk, and practical guidance for patients and prescribers.
Jardiance Patent & Generic Timeline: When Will Generic Empagliflozin Be Available?
A detailed analysis of empagliflozin (Jardiance) patent protections, Orange Book listings, Paragraph IV challenges, and projected generic entry dates based on current litigation and regulatory filings.
Jardiance Pre-Surgery Hold Window: Empagliflozin Perioperative Guidelines
Jardiance and anesthesia: hold empagliflozin 3 to 4 days before general or neuraxial anesthesia to cut euglycemic DKA risk; restart 24 to 48 hours post-op.
Jardiance Pregnancy Category: Not Recommended, FDA Data
Jardiance has no FDA pregnancy category; it's labeled not recommended. Animal studies show fetal kidney risks; no human trial data exists.
Jardiance Side Effects in Elderly: Risks and Monitoring
Main risks in older adults are genital infections, dehydration, and rare DKA. See EMPA-REG data and how doctors monitor kidney function and hydration.
Jardiance Storage, Stability & Shelf Life: Evidence-Based Handling Guide
How to store empagliflozin (Jardiance) correctly, what the FDA label and stability testing standards say about shelf life, and when to discard tablets exposed to heat or moisture.
Restarting Jardiance (Empagliflozin) After Acute Illness: A Clinical Guide
When and how to safely restart empagliflozin after illness, surgery, or hospitalization. Covers sick-day rules, DKA risk, renal thresholds, and a step-by-step restart protocol backed by primary literature.
SGLT2 Inhibitors Price Comparison (Jardiance, Farxiga, Invokana)
Jardiance and Farxiga run about $590-630/month; generic Invokana is projected at $50-150/month. Compare cost-per-outcome using EMPA-REG cardiovascular data.
Too Much Jardiance: What to Report and What the Evidence Shows
Took extra Jardiance? Know what to report to Poison Help, which symptoms need urgent care, and how to interpret the available overdose evidence.